Chimeric Therapeutics Limited (CHM.AX)

AUD 0.01

(-14.29%)

Annual Income Statements

(In AUD)
Breakdown 2024 2023 2022 2021 2020
Revenue 7.45 Million 4.5 Million 2.61 Million 2646.00 -
Cost of Revenue 3922.00 965.35 Thousand 949.76 Thousand 846.96 Thousand -
Gross Profit 7.45 Million 3.54 Million 1.66 Million -844.31 Thousand -
Operating Expenses 19.76 Million 28.52 Million 17.18 Million 14.84 Million 64 Thousand
Selling, General and Administrative Expenses 9.57 Million 15.04 Million 8.73 Million 5.82 Million 64 Thousand
Research and Development Expenses 11.14 Million 13.47 Million 5.17 Million 3.77 Million -
Other Expenses -951.86 Thousand 4.82 Million 3.35 Million -263.79 Thousand -
Cost and Expenses 19.76 Million 29.48 Million 17.18 Million 14.84 Million 64 Thousand
Operating Income -12.3 Million -29.48 Million -13.81 Million -15.1 Million -64.01 Thousand
Interest Expense 331.81 Thousand 773.84 Thousand 640.12 Thousand 5877.00 -
Income Tax Expense -3.75 Million -4.41 Million 163.72 Thousand -257.91 Thousand -153.62 Thousand
Earnings before Tax -16.28 Million -30.32 Million -14.45 Million -15.11 Million -64 Thousand
Net Income -12.52 Million -25.91 Million -14.62 Million -15.11 Million -64 Thousand
Earnings Per Share Basic -0.02 -0.06 -0.04 -0.05 -0.00
Earnings Per Share Diluted -0.02 -0.06 -0.04 -0.05 -0.00
Weighted Average Shares Outstanding 695.67 Million 433.24 Million 359.93 Million 325.51 Million 342.92 Million
Weighted Average Shares Outstanding (Diluted) 695.63 Million 433.24 Million 359.93 Million 325.5 Million 342.92 Million
Gross Margin 1.00 0.79 0.64 -319.09 -
EBIT Margin -1.52 -6.33 -4.92 -5708.69 -
Profit Margin -1.68 -5.75 -5.59 -5711.91 -
EBITDA -11.29 Million -24.01 Million -13.62 Million -13.99 Million -
Earnings Before Tax Margin -1.65 -6.54 -5.28 -5709.69 -

Income Statement Charts